FDA Approvals of Newer Drugs Bodes Well for Hemophilia Treatment Drugs Market

The global hemophilia treatment drugs market is on the verge of a major revolution as a gamut of new drugs are about to bring a sea of change for the treatment of various types of hemophilia. The new drugs tend to serve long-lasting clotting needs. For example, “emicizumab” developed by Roche is likely to arouse preventive faculty in individuals suffering from severe Hemophilia A. The adoption of prophylaxis practices to manage bleeding episodes by administering declotting concentrates is likely to propel the overall market.

The hemophilia treatment drugs market is also benefitting from increasing investments for the development of breakthrough products. For example, Pfizer and Spark Therapeutics obtained FDA approval for a novel drug in July 2016. “SPK-9001, as the drug is named is being recognized for a one-time therapy for treating Hemophilia B. Further, incentives received by orphan drugs in the form of tax credits, grants, and market exclusivity are likely to fuel the hemophilia treatment drugs market in the forthcoming years. Due to several positive factors, the hemophilia treatment drugs market is predicted to display steady growth in the forthcoming years, reports a new market study by Transparency Market Research (TMR).

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1900

Hemophilia Treatment Drugs Market: Segment Analysis

The various segments the hemophilia treatment drugs market is segmented based on product are recombinant coagulation factor concentrates, desmopressin, antifibrinolytic agents, and plasma derived coagulation factor concentrates. Of them, the segment of recombinant coagulation factor concentrates is likely to lead the market in the upcoming years. Recombinant coagulation factor concentrates are increasingly being preferred by medical practitioners as they carry low chance of blood borne infections.

The segment of recombinant coagulation factor concentrates accounted for the leading 46.6% share in the overall market in 2015. The components of recombinant coagulation factor concentrate segment are factor IX, factor VII, and combination drugs.

Request For Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=1900

Hemophilia Treatment Drugs Market: Regional Outlook

The key geographical regions into which the hemophilia treatment drugs market is divided are North America, Asia Pacific, Europe, Middle East and Africa, and  Latin America. Of them, North America is reported to dominate the hemophilia treatment drugs market; the region is likely to hold on to its position in the near future on the back of an ultra-modern healthcare infrastructure.

Besides this, a high level of awareness among individuals regarding therapeutics for hemophilia is likely to boost the growth of this regional market. At present, the U.S. is the leading domestic market for hemophilia treatment drugs in North America.

Meanwhile, Europe is predicted to lose its market share due to patent expiration of several blockbuster drugs. Asia Pacific is likely to emerge as lucrative market and present substantial revenue contribution to the overall market. Factors such as rising healthcare spending, improving healthcare facilities, and rising awareness about the disease in emerging economies of the region have spiked the hemophilia treatment drugs market.

Buy Hemophilia Treatment Drugs Market Research - https://www.transparencymarketresearch.com/checkout.php?rep_id=1900&ltype=S

Hemophilia Treatment Drugs Market: Major Players

The global market for hemophilia treatment drugs is largely consolidated with majority share held by top ten players vis-à-vis revenue. Of them, Novo Nordisk A/S, Pfizer Inc., and Shire Plc. raked in the lion’s share of 48.8% in the overall market in 2015. Savvy players are vying for strategic alliances to improve their research and development expertise with the focus to enhance their product portfolio.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.”

Contact
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/

Back to news